![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Acorda Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: Approved Product Type: Small molecule
Recipient: Acorda Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2022
Details:
Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: Approved Product Type: Small molecule
Recipient: Acorda Therapeutics
Deal Size: Undisclosed Upfront Cash: $5.6 million
Deal Type: Agreement November 09, 2021
Details:
Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: Approved Product Type: Small molecule
Recipient: Acorda Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 22, 2021
Details:
Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.
Lead Product(s): Celecoxib,Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: E-58425
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Kowa Pharmaceuticals America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2021